Impact of acellular immunization against pertussis; comparative experience of four countries in North, Central and South America.

IF 4.8 3区医学 Q1 IMMUNOLOGY

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-08-29 DOI:10.1080/14760584.2025.2550973

María L Avila-Aguero, Miguel Betancourt-Cravioto, Ruby Trejo Varon, Juan Pablo Torres, Ana G Lucas, Francisco Becerra-Posada, Carlos Espinal

{"title":"Impact of acellular immunization against pertussis; comparative experience of four countries in North, Central and South America.","authors":"María L Avila-Aguero, Miguel Betancourt-Cravioto, Ruby Trejo Varon, Juan Pablo Torres, Ana G Lucas, Francisco Becerra-Posada, Carlos Espinal","doi":"10.1080/14760584.2025.2550973","DOIUrl":null,"url":null,"abstract":"Introduction: Pertussis remains a public health concern despite widespread vaccination, due to waning immunity and asymptomatic transmission. The shift to acellular pertussis (aP) vaccines, aimed at reducing side effects, has changed disease dynamics, requiring ongoing evaluation.Areas covered: We examined immunization strategies and epidemiological trends in Chile, Costa Rica, Mexico, and Panama following aP vaccine introduction. Compared vaccine coverage (VC), maternal immunization (MI), and booster strategies (BS), and explored their role in disease control, including post-COVID-19 resurgence.Expert opinion: High aP VC and MI programs have reduced pertussis in Latin America (LATAM). However, waning immunity, uneven coverage, and disrupted surveillance pose challenges. Strengthening adolescent BS, expanding MI, and improving data systems are vital for sustained control.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"24 1","pages":"834-839"},"PeriodicalIF":4.8000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14760584.2025.2550973","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/29 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Pertussis remains a public health concern despite widespread vaccination, due to waning immunity and asymptomatic transmission. The shift to acellular pertussis (aP) vaccines, aimed at reducing side effects, has changed disease dynamics, requiring ongoing evaluation.

Areas covered: We examined immunization strategies and epidemiological trends in Chile, Costa Rica, Mexico, and Panama following aP vaccine introduction. Compared vaccine coverage (VC), maternal immunization (MI), and booster strategies (BS), and explored their role in disease control, including post-COVID-19 resurgence.

Expert opinion: High aP VC and MI programs have reduced pertussis in Latin America (LATAM). However, waning immunity, uneven coverage, and disrupted surveillance pose challenges. Strengthening adolescent BS, expanding MI, and improving data systems are vital for sustained control.

查看原文本刊更多论文

无细胞免疫对百日咳的影响北美洲、中美洲和南美洲四个国家的比较经验。

简介：百日咳仍然是一个公共卫生问题，尽管广泛接种疫苗，由于免疫力下降和无症状传播。转向无细胞百日咳（aP）疫苗，旨在减少副作用，已经改变了疾病动态，需要持续评估。覆盖地区：我们研究了在引进aP疫苗后智利、哥斯达黎加、墨西哥和巴拿马的免疫策略和流行病学趋势。比较疫苗覆盖率（VC）、孕产妇免疫（MI）和加强策略（BS），并探讨它们在疾病控制中的作用，包括covid -19后卷土重来。专家意见：高aP VC和MI计划减少了拉丁美洲（LATAM）的百日咳。然而，免疫力下降、覆盖不均匀和监测中断构成了挑战。加强青少年BS、扩大MI和改进数据系统对于持续控制至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Vaccines 医学-免疫学

CiteScore

9.10

自引率

3.20%

发文量

136

审稿时长

4-8 weeks

期刊介绍： Expert Review of Vaccines (ISSN 1476-0584) provides expert commentary on the development, application, and clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines for defence against bioterrorism. All articles are subject to rigorous peer-review. The vaccine field has been transformed by recent technological advances, but there remain many challenges in the delivery of cost-effective, safe vaccines. Expert Review of Vaccines facilitates decision making to drive forward this exciting field.